Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Akorn, Inc.
Akorn Acquires Capastat® Sulfate from Eli Lilly and Company
July 3rd, 2009
Akorn, Inc. (NASDAQ: AKRX) announced that it has entered into an agreement to acquire from Eli Lilly and Company (NYSE: LLY) all rights in the U.S. and Canada to manufacture, market and sell the lyophilized antibiotic Capastat® Sulfate (capreomycin for injection, USP). Akorn will own the Capastat NDA and expects to launch the product in the third quarter of this year. Raj Rai, Akorn's Interim Chief Executive Officer, stated, "Capastat represents an excellent fit within Akorn's strengths and capabilities. This product has been a mainstay in treating TB for over thirty years and complements Rifampin used in the treatment of tuberculosis, which Akorn currently markets...
Source: Health Business Week (2009-07-03)
|
